Published March 2022 | Version v1
Journal article

Endoscopic Follow-up of Low Grade Precancerous Bronchial Lesions in High-Risk Patients: long-term results of the SELEPREBB randomized multicentre trial

Others:
Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS) ; Université Le Havre Normandie (ULH) ; Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN) ; Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie) ; Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)
CHU Rouen ; Normandie Université (NU)
Centre Hospitalier Universitaire de Reims (CHU Reims)
Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
Institut de recherche en santé, environnement et travail (Irset) ; Université d'Angers (UA)-Université de Rennes 1 (UR1) ; Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
CHU Pontchaillou [Rennes]
Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND) ; Université de Rouen Normandie (UNIROUEN) ; Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen) ; Hôpital Charles Nicolle [Rouen]-CHU Rouen ; Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN) ; Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Description

Background Three to 9% of low-grade pre-invasive bronchial lesions progress to cancer. This study assessed the usefulness of an intensive bronchoscopy surveillance strategy in patients with bronchial lesions up to moderate squamous dysplasia. Methods SELEPREBB ( NCT00213603 ) was a randomized study conducted in 17 French centers. After baseline lung CT-scan and autofluorescence bronchoscopy (AFB) excluding lung cancer and bronchial severe squamous dysplasia or carcinoma in situ (CIS), patients were assigned to standard surveillance (arm A) with CT and AFB at 36 months or to intensive surveillance (arm B) including AFB every 6 months. Further long term data were obtained with a median follow-up of 4.7 years. Results 364 patients were randomized (A: 180, B: 184). Twenty-seven patients developed invasive lung cancer and 2 developed persistent CIS during the study, without difference between arms (OR=0.63, 95% CI=[0.20–1.96], p=0.42). Mild or moderate dysplasia at baseline bronchoscopy was a significant lung cancer risk factor both at 3 years (8/74 patients, OR=6.9, 95% CI=[2.5–18.9], p<0.001) and at maximum follow-up (16/74, patients, OR=5.9, 95% CI=[2.9–12.0]). Smoking cessation was significantly associated with clearance of bronchial dysplasia on follow-up (OR=0.12, 95% CI=[0.01–0.66], p=0.005) and with a reduced risk of lung cancer at 5 years (OR=0.15, 95% CI=[0.003–0.99], p=0.04). Conclusion Patients with mild or moderate dysplasia are at very high-risk for lung cancer at 5 years, with smoking cessation significantly reducing the risk. Whereas an intensive bronchoscopy surveillance does not improve patient's outcome, the identification of bronchial dysplasia using initial bronchoscopy maybe useful for risk stratification strategies in lung cancer screening programs.

Abstract

International audience

Additional details

Created:
December 3, 2022
Modified:
November 29, 2023